Hyperactivation of MAPK signaling in BRAFV600E-mutant melanoma cells leads to increased c-Jun expression, resulting in mesenchymal-like phenotype and resistance to BRAF/MEK inhibitors (MAPKi) (49). Here, BRAF is linked to melanoma.